Expression of RANKL in breast cancer tissue in patients with fibrous dysplasia/McCune-Albright syndrome
Maartje E. Meier(Leiden University Medical Center), N. Bravenboer(Leiden University Medical Center), B.C.J. Majoor(Leiden University Medical Center), Marlous Hagelstein-Rotman(Leiden University Medical Center), Natasha M. Appelman‐Dijkstra(Leiden University Medical Center), Raya E.S. Geels(Leiden University Medical Center)
Cited by 1
Related Papers
Poor sleep quality and later sleep timing are risk factors for osteopenia and sarcopenia in middle-aged men and women: The NEO study
|PLoS ONE|2017|113
Safety of therapy with and withdrawal from denosumab in fibrous dysplasia and McCune-Albright syndrome: an observational study
|Journal of Bone and Mineral Research|2020|49
Incidence and Prevalence of Fibrous Dysplasia/McCune-Albright Syndrome: A Nationwide Registry-Based Study in Denmark
|The Journal of Clinical Endocrinology & Metabolism|2024|29
Regression of fibrous dysplasia in response to denosumab therapy: A report of two cases
|Bone Reports|2021|28
Denosumab Reduces Lesional Fluoride Skeletal Burden on Na[18F]F PET-CT in Patients With Fibrous Dysplasia/McCune–Albright Syndrome
|The Journal of Clinical Endocrinology & Metabolism|2021|27